SYRE Positive Sentiment
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the Company or Spyre ), a development-stage biotechnology company advancing best-in-class antibody...
Monday, February 26, 2024 BiopharmaWatch Research 1 min read Key Takeaway: Spyre Therapeutics, a development-stage biotechnology company, will participate in the 44th Annual TD Cowen Health Care Conference on March 5, 2024. CEO Cameron Turtle will be part of a panel discussion focusing on Inflammation & Immunology. The event offers a platform for Spyre to present its advancements in antibody development. Additionally, a webcast will be available for public access following the conference.
Full Press Release Details
Cameron Turtle , Chief Executive Officer, will participate in the Inflammation & Immunology Corporate Panel Discussion on Tuesday, March 5, 2024 , at 2:10 p.m. Eastern time .
To access this webcast, please visit the "Events & Presentations" page within the Investors section of the Spyre website at ir.spyre.com. An archive of the webcast will be available for replay for 30 days following the end of the conference.
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
For Investor s : Eric McIntyre VP of Finance and Investor Relations Spyre Therapeutics [email protected]
For Media : Peg Rusconi Peg.rusconi@vergescientific. com